What Researchers Did
Researchers engaged three people with multiple sclerosis (MS) and an MS Centre manager to inform a laboratory study investigating the physiological effects of oxygen therapy on microvascular brain endothelial cells.
What They Found
They found that MS patients often use oxygen therapy at later stages, typically at 100% O2 at 1.5 atmosphere absolute (1140 mmHg absolute) for 60 minutes. In a lab setting, human brain endothelial cells exposed in vitro to 152 mmHg O2 for 60 minutes showed a significant reduction in ICAM-1 (CD54), a marker implicated in inflammatory cell margination across the blood-brain barrier.
What This Means for Canadian Patients
This research, informed by patient experience, helps understand potential physiological mechanisms of hyperbaric oxygen therapy for MS symptoms. It could guide future clinical trials to optimize treatment protocols and improve patient outcomes.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The study's primary physiological findings were from an in vitro lab experiment, and the patient involvement group was very small.